{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:29:12Z","timestamp":1790674152403,"version":"4.1.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-018-0763-x","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T10:49:43Z","timestamp":1524826183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma"],"prefix":"10.1186","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7214-647X","authenticated-orcid":false,"given":"Ruixia","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar K.","family":"Rofstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"issue":"1","key":"763_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"763_CR2","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/ibd.20501","volume":"14","author":"J Rivera-Nieves","year":"2008","unstructured":"Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(12):1715\u201335.","journal-title":"Inflamm Bowel Dis"},{"key":"763_CR3","doi-asserted-by":"publisher","unstructured":"Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3(3) https:\/\/doi.org\/10.1101\/cshperspect.a004994 .","DOI":"10.1101\/cshperspect.a004994"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0065-2776(06)91003-7","volume":"91","author":"DE Staunton","year":"2006","unstructured":"Staunton DE, Lupher ML, Liddington R, Gallatin WM. Targeting integrin structure and function in disease. Adv Immunol. 2006;91:111\u201357.","journal-title":"Adv Immunol"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"676731","DOI":"10.1155\/2012\/676731","volume":"2012","author":"G Bendas","year":"2012","unstructured":"Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731.","journal-title":"Int J Cell Biol"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1186\/s40064-016-2502-0","volume":"5","author":"L Pan","year":"2016","unstructured":"Pan L, Zhao Y, Yuan ZJ, Qin GX. Research advances on structure and biological functions of integrins. Spring. 2016;5:1094.","journal-title":"Spring"},{"issue":"2","key":"763_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0092-8674(89)90902-1","volume":"56","author":"LC Plantefaber","year":"1989","unstructured":"Plantefaber LC, Hynes RO. Changes in integrin receptors on Oncogenically transformed-cells. Cell. 1989;56(2):281\u201390.","journal-title":"Cell"},{"issue":"2","key":"763_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1755-148X.2010.00806.x","volume":"24","author":"P Pinon","year":"2011","unstructured":"Pinon P, Wehrle-Haller B. Integrins: versatile receptors controlling melanocyte adhesion, migration and proliferation. Pigm Cell Melanoma R. 2011;24(2):282\u201394.","journal-title":"Pigm Cell Melanoma R"},{"issue":"1","key":"763_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12033-007-0072-7","volume":"38","author":"SA Mousa","year":"2008","unstructured":"Mousa SA. Cell adhesion molecules: potential therapeutic & diagnostic implications. Mol Biotechnol. 2008;38(1):33\u201340.","journal-title":"Mol Biotechnol"},{"issue":"2","key":"763_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","volume":"11","author":"Z Ali","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013;11(2):81\u201391.","journal-title":"EJC Suppl"},{"issue":"Suppl 2","key":"763_CR11","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/modpathol.3800517","volume":"19","author":"AN Crowson","year":"2006","unstructured":"Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol. 2006;19(Suppl 2):S71\u201387.","journal-title":"Mod Pathol"},{"issue":"2","key":"763_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/1097-0142(19930715)72:2<455::AID-CNCR2820720222>3.0.CO;2-8","volume":"72","author":"A Vacca","year":"1993","unstructured":"Vacca A, Ribatti D, Roncali L, Lospalluti M, Serio G, Carrel S, Dammacco F. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer. 1993;72(2):455\u201361.","journal-title":"Cancer"},{"issue":"3","key":"763_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CMR.0000000000000322","volume":"27","author":"L Vizkeleti","year":"2017","unstructured":"Vizkeleti L, Kiss T, Koroknai V, Ecsedi S, Papp O, Szasz I, Adany R, Balazs M. Altered integrin expression patterns shown by microarray in human cutaneous melanoma. Melanoma Res. 2017;27(3):180\u20138.","journal-title":"Melanoma Res"},{"issue":"1","key":"763_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00008390-200402000-00005","volume":"14","author":"J Nikkola","year":"2004","unstructured":"Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhonen S. Integrin chains beta 1 and alpha v as prognostic factors in human metastatic melanoma. Melanoma Res. 2004;14(1):29\u201337.","journal-title":"Melanoma Res"},{"issue":"5","key":"763_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0046-8177(99)90202-2","volume":"30","author":"PA Van Belle","year":"1999","unstructured":"Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, et al. Progression-related expression of beta 3 integrin in melanomas and nevi. Hum Pathol. 1999;30(5):562\u20137.","journal-title":"Hum Pathol"},{"issue":"5","key":"763_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S0002-9440(10)65730-6","volume":"153","author":"MY Hsu","year":"1998","unstructured":"Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral gene transfer of beta 3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 1998;153(5):1435\u201342.","journal-title":"Am J Pathol"},{"issue":"9","key":"763_CR17","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1091\/mbc.12.9.2699","volume":"12","author":"EB Voura","year":"2001","unstructured":"Voura EB, Ramjeesingh RA, Montgomery AMP, Siu CH. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell. 2001;12(9):2699\u2013710.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"763_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jcp.21029","volume":"212","author":"M Klemke","year":"2007","unstructured":"Klemke M, Weschenfelder T, Konstandin MH, Samstag Y. High affinity interaction of integrin alpha 4 beta 1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol. 2007;212(2):368\u201374.","journal-title":"J Cell Physiol"},{"issue":"16","key":"763_CR19","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, et al. Final version of the American joint committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635\u201348.","journal-title":"J Clin Oncol"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"647684","DOI":"10.1155\/2012\/647684","volume":"2012","author":"F Tas","year":"2012","unstructured":"Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:647684.","journal-title":"J Oncol"},{"issue":"4","key":"763_CR21","first-page":"572","volume":"7","author":"A Sandru","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7(4):572\u20136.","journal-title":"J Med Life"},{"issue":"2","key":"763_CR22","first-page":"192","volume":"68","author":"J Vink","year":"1993","unstructured":"Vink J, Thomas L, Etoh T, Bruijn JA, Mihm MC, Gattonicelli S, Byers HR. Role of Beta-1 Integrins in organ specific adhesion of melanoma-cells Invitro. Lab Investig. 1993;68(2):192\u2013203.","journal-title":"Lab Investig"},{"issue":"2","key":"763_CR23","first-page":"375","volume":"85","author":"TJ Hieken","year":"1999","unstructured":"Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer-Am Cancer Soc. 1999;85(2):375\u201382.","journal-title":"Cancer-Am Cancer Soc"},{"issue":"4B","key":"763_CR24","first-page":"2321","volume":"16","author":"TJ Hieken","year":"1996","unstructured":"Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Beta 1 integrin expression: a marker of lymphatic metastases in cutaneous malignant melanoma. Anticancer Res. 1996;16(4B):2321\u20134.","journal-title":"Anticancer Res"},{"issue":"4","key":"763_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0039-6060(05)80034-0","volume":"118","author":"TJ Hieken","year":"1995","unstructured":"Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Kim DK, Dasgupta TK. Beta(1) integrin expression in malignant-melanoma predicts occult lymph-node metastases. Surgery. 1995;118(4):669\u201375.","journal-title":"Surgery"},{"issue":"2","key":"763_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.molonc.2011.01.003","volume":"5","author":"I Helfrich","year":"2011","unstructured":"Helfrich I, Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? Mol Oncol. 2011;5(2):137\u201349.","journal-title":"Mol Oncol"},{"issue":"7","key":"763_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.molmed.2011.01.015","volume":"17","author":"P Saharinen","year":"2011","unstructured":"Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011;17(7):347\u201362.","journal-title":"Trends Mol Med"},{"issue":"10","key":"763_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/ATVBAHA.108.172015","volume":"28","author":"R Silva","year":"2008","unstructured":"Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE. Integrins - the keys to unlocking angiogenesis. Arterioscl Throm Vas. 2008;28(10):1703\u201313.","journal-title":"Arterioscl Throm Vas"},{"issue":"22","key":"763_CR29","doi-asserted-by":"publisher","first-page":"9042","DOI":"10.1073\/pnas.1219603110","volume":"110","author":"B Garmy-Susini","year":"2013","unstructured":"Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, et al. PI3K alpha activates integrin alpha 4 beta 1 to establish a metastatic niche in lymph nodes. P Natl Acad Sci USA. 2013;110(22):9042\u20137.","journal-title":"P Natl Acad Sci USA"},{"issue":"6","key":"763_CR30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/CIRCRESAHA.107.155655","volume":"101","author":"GH Mahabeleshwar","year":"2007","unstructured":"Mahabeleshwar GH, Feng WY, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res. 2007;101(6):570\u201380.","journal-title":"Circ Res"},{"issue":"203","key":"763_CR31","doi-asserted-by":"publisher","first-page":"203ra127","DOI":"10.1126\/scitranslmed.3006666","volume":"5","author":"J Lee","year":"2013","unstructured":"Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, Shioi G, Chang W, Suda T, Mochizuki N, et al. Angiopoietin-1 guides directional angiogenesis through integrin alpha(v)beta(5) signaling for recovery of ischemic retinopathy. Sci Transl Med. 2013;5(203):203ra127.","journal-title":"Sci Transl Med"},{"issue":"6","key":"763_CR32","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI58832","volume":"122","author":"M Felcht","year":"2012","unstructured":"Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu JH, Bartol A, Kienast Y, Vettel C, Loos EK, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012;122(6):1991\u20132005.","journal-title":"J Clin Invest"},{"issue":"6","key":"763_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1083\/jcb.200507082","volume":"170","author":"I Cascone","year":"2005","unstructured":"Cascone I, Napione L, Maniero F, Serini G, Bussolino F. Stable interaction between alpha 5 beta 1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol. 2005;170(6):993\u20131004.","journal-title":"J Cell Biol"},{"issue":"1","key":"763_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI119500","volume":"100","author":"SJ Shattil","year":"1997","unstructured":"Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest. 1997;100(1):1\u20135.","journal-title":"J Clin Invest"},{"issue":"21","key":"763_CR35","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.1073\/pnas.0502935102","volume":"102","author":"S De","year":"2005","unstructured":"De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. P Natl Acad Sci USA. 2005;102(21):7589\u201394.","journal-title":"P Natl Acad Sci USA"},{"issue":"3","key":"763_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4161\/cc.7.3.5234","volume":"7","author":"GH Mahabeleshwar","year":"2008","unstructured":"Mahabeleshwar GH, Chen JH, Feng WY, Somanath PR, Razorenova OV, Byzova TV. Integrin affinity modulation in angiogenesis. Cell Cycle. 2008;7(3):335\u201347.","journal-title":"Cell Cycle"},{"issue":"1","key":"763_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ijc.20991","volume":"116","author":"B Dome","year":"2005","unstructured":"Dome B, Raso E, Dobos J, Meszaros L, Varga N, Puskas LG, Feher LZ, Lorincz T, Ladanyi A, Trikha M, et al. Parallel expression of alpha IIb beta 3 and alpha v beta 3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype. Int J Cancer. 2005;116(1):27\u201335.","journal-title":"Int J Cancer"},{"issue":"7","key":"763_CR38","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","volume":"79","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu TH, Klier G, Cheresh DA. Integrin alpha(V)Beta(3) antagonists promote tumor-regression by inducing apoptosis of Angiogenic blood-vessels. Cell. 1994;79(7):1157\u201364.","journal-title":"Cell"},{"issue":"6","key":"763_CR39","doi-asserted-by":"publisher","first-page":"E545","DOI":"10.1002\/ijc.29252","volume":"136","author":"F Ruffini","year":"2015","unstructured":"Ruffini F, Graziani G, Levati L, Tentori L, D'Atri S, Lacal PM. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of alpha v beta 5 integrin. Int J Cancer. 2015;136(6):E545\u201358.","journal-title":"Int J Cancer"},{"issue":"2","key":"763_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ydbio.2008.01.022","volume":"316","author":"A Pozzi","year":"2008","unstructured":"Pozzi A, Jarad G, Moeckel GW, Coffa S, Zhang X, Gewin L, Eremina V, Hudson BG, Borza DB, Harris RC, et al. Beta 1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol. 2008;316(2):288\u2013301.","journal-title":"Dev Biol"},{"key":"763_CR41","doi-asserted-by":"crossref","unstructured":"Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P. Endothelial destabilization by angiopoietin-2 via integrin beta 1 activation. Nat Commun. 2015;6","DOI":"10.1038\/ncomms6962"},{"issue":"20","key":"763_CR42","first-page":"6751","volume":"63","author":"AR Cardones","year":"2003","unstructured":"Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res. 2003;63(20):6751\u20137.","journal-title":"Cancer Res"},{"issue":"10","key":"763_CR43","doi-asserted-by":"publisher","first-page":"e46576","DOI":"10.1371\/journal.pone.0046576","volume":"7","author":"H Kato","year":"2012","unstructured":"Kato H, Liao ZJ, Mitsios JV, Wang HY, Deryugina EI, Varner JA, Quigley JP, Shattil SJ. The primacy of beta 1 integrin activation in the metastatic Cascade. PLoS One. 2012;7(10):e46576.","journal-title":"PLoS One"},{"issue":"6","key":"763_CR44","doi-asserted-by":"publisher","first-page":"e5857","DOI":"10.1371\/journal.pone.0005857","volume":"4","author":"WS Carbonell","year":"2009","unstructured":"Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as \u201csoil\u201d in brain metastasis. PLoS One. 2009;4(6):e5857.","journal-title":"PLoS One"},{"key":"763_CR45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijbiomac.2017.05.093","volume":"103","author":"YQ Liu","year":"2017","unstructured":"Liu YQ, Zou XM, Sun GR, Bao YH. Codonopsis lanceolata polysaccharide CLPS inhibits melanoma metastasis via regulating integrin signaling. Int J Biol Macromol. 2017;103:435\u201340.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"763_CR46","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0002-9440(10)65005-5","volume":"156","author":"S Kim","year":"2000","unstructured":"Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha 5 beta 1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156(4):1345\u201362.","journal-title":"Am J Pathol"},{"issue":"1","key":"763_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.expneurol.2012.06.005","volume":"237","author":"LX Li","year":"2012","unstructured":"Li LX, Welser-Alves J, van der Flier A, Boroujerdi A, Hynes RO, Milner R. An angiogenic role for the alpha 5 beta 1 integrin in promoting endothelial cell proliferation during cerebral hypoxia. Exp Neurol. 2012;237(1):46\u201354.","journal-title":"Exp Neurol"},{"issue":"20","key":"763_CR48","doi-asserted-by":"publisher","first-page":"15187","DOI":"10.1074\/jbc.M609323200","volume":"282","author":"NE Vlahakis","year":"2007","unstructured":"Vlahakis NE, Young BA, Atakilit A, Hawkridge AE, Issaka RB, Boudreau N, Sheppard D. Integrin alpha 9 beta 1 directly binds to vascular endothelial growth factor (VEGF)- a and contributes to VEGF-A-induced angiogenesis. J Biol Chem. 2007;282(20):15187\u201396.","journal-title":"J Biol Chem"},{"issue":"19","key":"763_CR49","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1182\/blood-2010-02-270819","volume":"116","author":"R del Toro","year":"2010","unstructured":"del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, Breant C, Duarte A, Takakura N, Fukamizu A, et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood. 2010;116(19):4025\u201333.","journal-title":"Blood"},{"issue":"31","key":"763_CR50","doi-asserted-by":"publisher","first-page":"23842","DOI":"10.1074\/jbc.M109.097543","volume":"285","author":"M Thomas","year":"2010","unstructured":"Thomas M, Felcht M, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, Rohr K, Benest AV, Fiedler U, Augustin HG. Angiopoietin-2 stimulation of endothelial cells induces alpha v beta 3 integrin internalization and degradation. J Biol Chem. 2010;285(31):23842\u20139.","journal-title":"J Biol Chem"},{"issue":"8","key":"763_CR51","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc2353","volume":"8","author":"CJ Avraamides","year":"2008","unstructured":"Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8(8):604\u201317.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"763_CR52","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1074\/jbc.M412816200","volume":"280","author":"NE Vlahakis","year":"2005","unstructured":"Vlahakis NE, Young BA, Atakilit A, Sheppard D. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha 9 beta 1. J Biol Chem. 2005;280(6):4544\u201352.","journal-title":"J Biol Chem"},{"issue":"4B","key":"763_CR53","first-page":"2321","volume":"16","author":"TJ Hieken","year":"1996","unstructured":"Hieken TJ, Ronan SG, Farolan N, Shilkaitis AL, TK DG. Beta 1 integrin expression: a marker of lymphatic metastases in cutaneous malignant melanoma. Anticancer Res. 1996;16(4B):2321\u20134.","journal-title":"Anticancer Res"},{"issue":"6","key":"763_CR54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ar.23338","volume":"299","author":"XH Lv","year":"2016","unstructured":"Lv XH, Liu BQ, Li XM, Wang XC, Li XL, Ahmed N, Zhang YF. Integrin alpha 4 induces Lymphangiogenesis and metastasis via upregulation of VEGF-C in human Colon Cancer. Anat Rec. 2016;299(6):741\u20137.","journal-title":"Anat Rec"},{"issue":"2","key":"763_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1593\/neo.91604","volume":"12","author":"RB Rebhun","year":"2010","unstructured":"Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RR. Constitutive expression of the alpha(4) integrin correlates with Tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia. 2010;12(2):173\u201382.","journal-title":"Neoplasia"},{"issue":"2","key":"763_CR56","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98\u2013101.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"763_CR57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, Zhang HY, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang YB, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302\u201317.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"763_CR58","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/fon.14.26","volume":"10","author":"E Aladowicz","year":"2014","unstructured":"Aladowicz E, Lanfrancone L. Investigating the metastatic niche in melanoma: a new therapeutic opportunity? Future Oncol. 2014;10(5):699\u2013701.","journal-title":"Future Oncol"},{"issue":"4","key":"763_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrc2621","volume":"9","author":"B Psaila","year":"2009","unstructured":"Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"763_CR60","first-page":"2281","volume":"40","author":"IR Hart","year":"1980","unstructured":"Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 1980;40(7):2281\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"763_CR61","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/jnci\/57.5.1199","volume":"57","author":"IJ Fidler","year":"1976","unstructured":"Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst. 1976;57(5):1199\u2013202.","journal-title":"J Natl Cancer Inst"},{"key":"763_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ceb.2014.05.004","volume":"29","author":"J Kowal","year":"2014","unstructured":"Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014;29:116\u201325.","journal-title":"Curr Opin Cell Biol"},{"issue":"7578","key":"763_CR63","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nature15642","volume":"527","author":"J Rak","year":"2015","unstructured":"Rak J. Cancer: organ-seeking vesicles. Nature. 2015;527(7578):312\u20134.","journal-title":"Nature"},{"issue":"12","key":"763_CR64","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nrc4046","volume":"15","author":"GK Alderton","year":"2015","unstructured":"Alderton GK. Directions to metastatic sites. Nat Rev Cancer. 2015;15(12):696\u20137.","journal-title":"Nat Rev Cancer"},{"issue":"7578","key":"763_CR65","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Mark MT, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329\u201335.","journal-title":"Nature"},{"key":"763_CR66","doi-asserted-by":"publisher","unstructured":"Paolillo M, Schinelli S. Integrins and exosomes, a dangerous liaison in Cancer progression. Cancers. 2017;9(8) https:\/\/doi.org\/10.3390\/cancers9080095 .","DOI":"10.3390\/cancers9080095"},{"issue":"7","key":"763_CR67","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1600-0560.2008.01166.x","volume":"36","author":"K Doeden","year":"2009","unstructured":"Doeden K, Ma Z, Narasimhan B, Swetter SM, Detmar M, Dadras SS. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol. 2009;36(7):772\u201380.","journal-title":"J Cutan Pathol"},{"key":"763_CR68","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-62703-727-3_15","volume":"1102","author":"X Xu","year":"2014","unstructured":"Xu X, Gimotty PA, Guerry D, Karakousis G, Elder DE. Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma. Methods Mol Biol. 2014;1102:275\u201386.","journal-title":"Methods Mol Biol"},{"issue":"9","key":"763_CR69","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/modpathol.3800410","volume":"18","author":"SS Dadras","year":"2005","unstructured":"Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005;18(9):1232\u201342.","journal-title":"Mod Pathol"},{"issue":"8","key":"763_CR70","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/0008-5472.CAN-09-3761","volume":"70","author":"B Garmy-Susini","year":"2010","unstructured":"Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL, et al. Integrin alpha 4 beta 1 signaling is required for Lymphangiogenesis and tumor metastasis. Cancer Res. 2010;70(8):3042\u201351.","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"763_CR71","first-page":"S274","volume":"5","author":"PP Velu","year":"2013","unstructured":"Velu PP, Cao C, Yan TD. Current surgical management of melanoma metastases to the lung. J Thorac Dis. 2013;5(Suppl 3):S274\u20136.","journal-title":"J Thorac Dis"},{"key":"763_CR72","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12967-017-1307-4","volume":"15","author":"RX Huang","year":"2017","unstructured":"Huang RX, Andersen LMK, Rofstad EK. Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts. J Transl Med. 2017;15:203.","journal-title":"J Transl Med"},{"issue":"2","key":"763_CR73","doi-asserted-by":"publisher","first-page":"R20","DOI":"10.1186\/bcr1398","volume":"8","author":"EK Sloan","year":"2006","unstructured":"Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, Anderson RL. Tumor-specific expression of alpha v beta 3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006;8(2):R20.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"763_CR74","doi-asserted-by":"publisher","first-page":"e0172788","DOI":"10.1371\/journal.pone.0172788","volume":"12","author":"K Echtler","year":"2017","unstructured":"Echtler K, Konrad I, Lorenz M, Schneider S, Hofmaier S, Plenagl F, Stark K, Czermak T, Tirniceriu A, Eichhorn M, et al. Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis. PLoS One. 2017;12(3):e0172788.","journal-title":"PLoS One"},{"issue":"25","key":"763_CR75","doi-asserted-by":"publisher","first-page":"10290","DOI":"10.1073\/pnas.0904227106","volume":"106","author":"T Shibue","year":"2009","unstructured":"Shibue T, Weinberg RA. Integrin beta(1)-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. P Natl Acad Sci USA. 2009;106(25):10290\u20135.","journal-title":"P Natl Acad Sci USA"},{"issue":"6","key":"763_CR76","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.3892\/or.2015.3910","volume":"33","author":"M Pickarski","year":"2015","unstructured":"Pickarski M, Gleason A, Bednar B, Duong L. Orally active alpha v beta 3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015;33(6):2737\u201345.","journal-title":"Oncol Rep"},{"issue":"4","key":"763_CR77","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/0008-5472.CAN-08-3612","volume":"69","author":"JM Ricono","year":"2009","unstructured":"Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK, Cheresh DA. Specific cross-talk between epidermal growth factor receptor and integrin alpha(v)beta(5) promotes carcinoma cell invasion and metastasis. Cancer Res. 2009;69(4):1383\u201391.","journal-title":"Cancer Res"},{"issue":"5","key":"763_CR78","doi-asserted-by":"publisher","first-page":"e36753","DOI":"10.1371\/journal.pone.0036753","volume":"7","author":"SKM Lau","year":"2012","unstructured":"Lau SKM, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, et al. EGFR-mediated carcinoma cell metastasis mediated by integrin alpha v beta 5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012;7(5):e36753.","journal-title":"PLoS One"},{"issue":"22","key":"763_CR79","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1038\/onc.2011.450","volume":"31","author":"M Huang","year":"2012","unstructured":"Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA. EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene. 2012;31(22):2783\u201393.","journal-title":"Oncogene"},{"issue":"3","key":"763_CR80","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1165\/rcmb.2006-0238OC","volume":"36","author":"G Su","year":"2007","unstructured":"Su G, Hodnett M, Wu NY, Atakilit A, Kosinski C, Godzich M, Huang XZ, Kim JYK, Frank JA, Matthay MA, et al. Integrin alpha v beta 5 regulates lung vascular permeability and pulmonary endothelial barrier function. Am J Resp Cell Mol. 2007;36(3):377\u201386.","journal-title":"Am J Resp Cell Mol"},{"issue":"34","key":"763_CR81","doi-asserted-by":"publisher","first-page":"55141","DOI":"10.18632\/oncotarget.10461","volume":"7","author":"A Gvozdenovic","year":"2016","unstructured":"Gvozdenovic A, Boro A, Meier D, Bode-Lesniewska B, Born W, Muff R, Fuchs B. Targeting alpha v beta 3 and alpha v beta 5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model. Oncotarget. 2016;7(34):55141\u201354.","journal-title":"Oncotarget"},{"issue":"1","key":"763_CR82","doi-asserted-by":"publisher","first-page":"215","DOI":"10.18632\/oncotarget.13832","volume":"8","author":"RA Bartolome","year":"2017","unstructured":"Bartolome RA, Torres S, de Val SI, Escudero-Paniagua B, Calvino E, Teixido J, Casal JI. VE-cadherin RGD motifs promote metastasis and constitute a potential therapeutic target in melanoma and breast cancers. Oncotarget. 2017;8(1):215\u201327.","journal-title":"Oncotarget"},{"key":"763_CR83","doi-asserted-by":"crossref","unstructured":"Bartolome RA, Aizpurua C, Jaen M, Torres S, Calvino E, Imbaud JI, Casal JI. Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal Cancer metastasis. Clin Cancer Res. 2018;24(2):433-44.","DOI":"10.1158\/1078-0432.CCR-17-1444"},{"issue":"21","key":"763_CR84","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1073\/pnas.88.21.9568","volume":"88","author":"DZ Zhu","year":"1991","unstructured":"Zhu DZ, Cheng CF, Pauli BU. Mediation of lung metastasis of murine melanomas by a lung-specific endothelial-cell adhesion molecule. P Natl Acad Sci USA. 1991;88(21):9568\u201372.","journal-title":"P Natl Acad Sci USA"},{"issue":"27","key":"763_CR85","doi-asserted-by":"publisher","first-page":"25438","DOI":"10.1074\/jbc.M100478200","volume":"276","author":"M Abdel-Ghany","year":"2001","unstructured":"Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. The breast cancer beta(4) integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem. 2001;276(27):25438\u201346.","journal-title":"J Biol Chem"},{"issue":"1","key":"763_CR86","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1148\/radiology.213.1.r99oc0992","volume":"213","author":"SP Blake","year":"1999","unstructured":"Blake SP, Weisinger K, Atkins MB, Raptopoulos V. Liver metastases from melanoma: detection with multiphasic contrast-enhanced CT. Radiology. 1999;213(1):92\u20136.","journal-title":"Radiology"},{"key":"763_CR87","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1038\/ncomms12502","volume":"7","author":"K Martin","year":"2016","unstructured":"Martin K, Pritchett J, Llewellyn J, Mullan AF, Athwal VS, Dobie R, Harvey E, Zeef L, Farrow S, Streuli C, et al. PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun. 2016;7:12502.","journal-title":"Nat Commun"},{"issue":"3","key":"763_CR88","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1478-3231.2004.0914.x","volume":"24","author":"GGM Pinkse","year":"2004","unstructured":"Pinkse GGM, Voorhoeve MP, Noteborn M, Terpstra OT, Bruijn JA, de Heer E. Hepatocyte survival depends on beta 1-integrin-mediated attachment of hepatocytes to hepatic extracellular matrix. Liver Int. 2004;24(3):218\u201326.","journal-title":"Liver Int"},{"issue":"3","key":"763_CR89","first-page":"G425","volume":"301","author":"E Patsenker","year":"2011","unstructured":"Patsenker E, Stickel F. Role of integrins in fibrosing liver diseases. Am J Physiol-Gastr L. 2011;301(3):G425\u201334.","journal-title":"Am J Physiol-Gastr L"},{"key":"763_CR90","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The role of Cancer-associated fibroblasts and fibrosis in liver Cancer. Annu Rev Pathol-Mech. 2017;12:153\u201386.","journal-title":"Annu Rev Pathol-Mech"},{"issue":"3\u20134","key":"763_CR91","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000343851","volume":"2","author":"T Sakurai","year":"2013","unstructured":"Sakurai T, Kudo M. Molecular link between liver fibrosis and hepatocellular carcinoma. Liver Cancer. 2013;2(3\u20134):365\u20136.","journal-title":"Liver Cancer"},{"issue":"18","key":"763_CR92","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1158\/0008-5472.CAN-09-0315","volume":"69","author":"K Yoshimura","year":"2009","unstructured":"Yoshimura K, Meckel KF, Laird LS, Chia CY, Park JJ, Olino KL, Tsunedomi R, Harada T, Iizuka N, Hazama S, et al. Integrin alpha 2 mediates selective metastasis to the liver. Cancer Res. 2009;69(18):7320\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"763_CR93","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/hep.22013","volume":"47","author":"GJ van der Bij","year":"2008","unstructured":"van der Bij GJ, Oosterfing SJ, Bogels M, Bhoelan F, Fluitsma DM, Beelen RHJ, Meijer S, van Egmond M. Blocking alpha 2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology. 2008;47(2):532\u201343.","journal-title":"Hepatology"},{"issue":"13","key":"763_CR94","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/onc.2010.532","volume":"30","author":"AK Mitra","year":"2011","unstructured":"Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011;30(13):1566\u201376.","journal-title":"Oncogene"},{"issue":"4","key":"763_CR95","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ijc.10958","volume":"104","author":"O Stoeltzing","year":"2003","unstructured":"Stoeltzing O, Liu WB, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM. Inhibition of integrin alpha(5)beta(1) function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003;104(4):496\u2013503.","journal-title":"Int J Cancer"},{"issue":"2","key":"763_CR96","doi-asserted-by":"publisher","first-page":"607","DOI":"10.21873\/anticanres.11354","volume":"37","author":"SH Ryu","year":"2017","unstructured":"Ryu SH, Heo SH, Park EY, Choi KC, Ryu JW, Lee SH, Lee SW. Selumetinib inhibits melanoma metastasis to mouse liver via suppression of EMT-targeted genes. Anticancer Res. 2017;37(2):607\u201314.","journal-title":"Anticancer Res"},{"issue":"1","key":"763_CR97","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2010.09.016","volume":"48","author":"JG Schneider","year":"2011","unstructured":"Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone. 2011;48(1):54\u201365.","journal-title":"Bone"},{"issue":"1","key":"763_CR98","first-page":"55","volume":"148","author":"N Matsuura","year":"1996","unstructured":"Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol. 1996;148(1):55\u201361.","journal-title":"Am J Pathol"},{"issue":"4","key":"763_CR99","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/jcb.21298","volume":"101","author":"C Hayashi","year":"2007","unstructured":"Hayashi C, Rittling S, Hayata T, Amagasa T, Denhardt D, Ezura Y, Nakashima K, Noda M. Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem. 2007;101(4):979\u201386.","journal-title":"J Cell Biochem"},{"issue":"10","key":"763_CR100","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1359\/jbmr.2004.19.10.1706","volume":"19","author":"Y Ohyama","year":"2004","unstructured":"Ohyama Y, Nemoto H, Rittling S, Tsuji K, Amagasa T, Denhardt DT, Nifuji A, Noda M. Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res. 2004;19(10):1706\u201311.","journal-title":"J Bone Miner Res"},{"issue":"24","key":"763_CR101","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.2234372100","volume":"100","author":"SJ Bakewell","year":"2003","unstructured":"Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, et al. Platelet and osteoclast beta(3) integrins are critical for bone metastasis. P Natl Acad Sci USA. 2003;100(24):14205\u201310.","journal-title":"P Natl Acad Sci USA"},{"issue":"4","key":"763_CR102","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.2660","volume":"220","author":"AR Watson","year":"2010","unstructured":"Watson AR, Pitchford SC, Reynolds LE, Direkze N, Brittan M, Alison MR, Rankin S, Wright NA, Hodivala-Dilke KM. Deficiency of bone marrow beta3-integrin enhances non-functional neovascularization. J Pathol. 2010;220(4):435\u201345.","journal-title":"J Pathol"},{"issue":"6","key":"763_CR103","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673\u201387.","journal-title":"Cell"},{"issue":"3","key":"763_CR104","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1074\/jbc.M111.269811","volume":"287","author":"AS Lonsdorf","year":"2012","unstructured":"Lonsdorf AS, Kramer BF, Fahrleitner M, Schonberger T, Gnerlich S, Ring S, Gehring S, Schneider SW, Kruhlak MJ, Meuth SG, et al. Engagement of alphaIIbbeta3 (GPIIb\/IIIa) with alphanubeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. J Biol Chem. 2012;287(3):2168\u201378.","journal-title":"J Biol Chem"},{"issue":"3","key":"763_CR105","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0092-8674(91)90451-4","volume":"65","author":"DR Phillips","year":"1991","unstructured":"Phillips DR, Charo IF, Scarborough RM. Gpiib-Iiia - the responsive integrin. Cell. 1991;65(3):359\u201362.","journal-title":"Cell"},{"issue":"12","key":"763_CR106","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/neuonc\/not112","volume":"15","author":"AS Berghoff","year":"2013","unstructured":"Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro-Oncology. 2013;15(12):1664\u201372.","journal-title":"Neuro-Oncology"},{"issue":"15","key":"763_CR107","first-page":"1664","volume":"31","author":"AS Berghoff","year":"2013","unstructured":"Berghoff AS, Rajky O, Winkler F, Weller M, Zielinski C, Schittenhelm J, Preusser M. Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers. J Clin Oncol. 2013;31(15):1664\u201372.","journal-title":"J Clin Oncol"},{"issue":"10","key":"763_CR108","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1002\/ijc.28267","volume":"133","author":"A Vogetseder","year":"2013","unstructured":"Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H. Alpha v-integrin isoform expression in primary human tumors and brain metastases. Int J Cancer. 2013;133(10):2362\u201371.","journal-title":"Int J Cancer"},{"issue":"7","key":"763_CR109","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10585-014-9675-0","volume":"31","author":"AS Berghoff","year":"2014","unstructured":"Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, et al. Alpha v beta 3, alpha v beta 5 and alpha v beta 6 integrins in brain metastases of lung cancer. Clin Exp Metastas. 2014;31(7):841\u201351.","journal-title":"Clin Exp Metastas"},{"issue":"8","key":"763_CR110","first-page":"4029","volume":"37","author":"YJ Wu","year":"2017","unstructured":"Wu YJ, Pagel MA, Muldoon LL, Fu R, Neuwelt EA. High alphav integrin level of Cancer cells is associated with development of brain metastasis in Athymic rats. Anticancer Res. 2017;37(8):4029\u201340.","journal-title":"Anticancer Res"},{"issue":"2","key":"763_CR111","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1173>3.0.CO;2-L","volume":"92","author":"B Kusters","year":"2001","unstructured":"Kusters B, Westphal JR, Smits D, Ruiter DJ, Wesseling P, Keilholz U, De Waal RMW. The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin alpha(v)beta(3) expression. Int J Cancer. 2001;92(2):176\u201380.","journal-title":"Int J Cancer"},{"key":"763_CR112","doi-asserted-by":"publisher","first-page":"154","DOI":"10.7150\/thno\/v01p0154","volume":"1","author":"M Millard","year":"2011","unstructured":"Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 2011;1:154\u201388.","journal-title":"Theranostics"},{"issue":"3","key":"763_CR113","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ijc.20116","volume":"110","author":"M Trikha","year":"2004","unstructured":"Trikha M, Zhou Z, Nemeth JA, Chen QM, Sharp C, Emmell E, Giles-Komar J, Nakada MT. CNTO 95, a fully human monoclonal antibody that inhibits alpha v integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer. 2004;110(3):326\u201335.","journal-title":"Int J Cancer"},{"issue":"6","key":"763_CR114","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1158\/1535-7163.MCT-08-0288","volume":"7","author":"SC Ning","year":"2008","unstructured":"Ning SC, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther. 2008;7(6):1569\u201378.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"763_CR115","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s10637-011-9639-z","volume":"30","author":"SJ O'day","year":"2012","unstructured":"O'day SJ, Pavlick AC, Albertini MR, Hamid O, Schalch H, Lang ZH, Ling J, Mata M, Reddy M, Foster B. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drug. 2012;30(3):1074\u201381.","journal-title":"Invest New Drug"},{"issue":"3","key":"763_CR116","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/bjc.2011.183","volume":"105","author":"S O'day","year":"2011","unstructured":"O'day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, et al. A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma. Brit J Cancer. 2011;105(3):346\u201352.","journal-title":"Brit J Cancer"},{"issue":"1","key":"763_CR117","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CMR.0b013e32834d3da0","volume":"22","author":"DW Robinson","year":"2012","unstructured":"Robinson DW, Cormier JN, Zhao N, Uhlar CM, Revicki DA, Cella D. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study. Melanoma Res. 2012;22(1):54\u201362.","journal-title":"Melanoma Res"},{"key":"763_CR118","unstructured":"\u201cIntetumumab\u201d. AdisInsight ( https:\/\/adisinsight.springer.com\/drugs\/800019252 ). Retrieved\u00a024 March\u00a02018."},{"issue":"8","key":"763_CR119","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/annonc\/mdm140","volume":"18","author":"S Hariharan","year":"2007","unstructured":"Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, et al. Assessment of the biological and pharmacological effects of the alpha(nu)beta(3) and alpha(nu)beta(5) integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007;18(8):1400\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"763_CR120","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/CMR.0b013e32835312e4","volume":"22","author":"KB Kim","year":"2012","unstructured":"Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, et al. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res. 2012;22(4):294\u2013301.","journal-title":"Melanoma Res"},{"issue":"6","key":"763_CR121","first-page":"677","volume":"29","author":"W Wang","year":"2006","unstructured":"Wang W, Rao U, Jukic D, Sander C, Drogowski L, Mandic M, Richman L, Tice D, Lieberman R, Hammershaimb L, et al. Phase I study of humanized anti-av beta 33 antibody MEDI-522 with tumor biopsy evaluation for saturation and antitumor effects in patients with metastatic melanoma. J Immunother. 2006;29(6):677.","journal-title":"J Immunother"},{"issue":"16","key":"763_CR122","first-page":"711s","volume":"23","author":"P Hersey","year":"2005","unstructured":"Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Kirkwood JM, et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, +\/\u2212 dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol. 2005;23(16):711s.","journal-title":"J Clin Oncol"},{"issue":"6","key":"763_CR123","first-page":"1526","volume":"116","author":"P Hersey","year":"2010","unstructured":"Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, et al. A randomized phase 2 study of Etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), +\/\u2212 Dacarbazine in patients with stage IV metastatic melanoma. Cancer-Am Cancer Soc. 2010;116(6):1526\u201334.","journal-title":"Cancer-Am Cancer Soc"},{"issue":"11","key":"763_CR124","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.str.2017.09.007","volume":"25","author":"AJ Borst","year":"2017","unstructured":"Borst AJ, James ZM, Zagotta WN, Ginsberg M, Rey FA, DiMaio F, Backovic M, Veesler D. The therapeutic antibody LM609 selectively inhibits ligand binding to human alpha(V)beta(3) integrin via steric hindrance. Structure. 2017;25(11):1732\u20131739.e5.","journal-title":"Structure"},{"issue":"4","key":"763_CR125","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1172\/JCI118227","volume":"96","author":"PC Brooks","year":"1995","unstructured":"Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha-V-Beta-3 blocks human breast-Cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96(4):1815\u201322.","journal-title":"J Clin Invest"},{"issue":"11","key":"763_CR126","first-page":"2724","volume":"59","author":"E Petitclerc","year":"1999","unstructured":"Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AMP, Cheresh DA, Brooks PC. Integrin alpha(V)beta(3) promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 1999;59(11):2724\u201330.","journal-title":"Cancer Res"},{"issue":"8","key":"763_CR127","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/onc.2009.408","volume":"29","author":"J Bai","year":"2010","unstructured":"Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, et al. JWA regulates melanoma metastasis by integrin alpha(V)beta(3) signaling. Oncogene. 2010;29(8):1227\u201337.","journal-title":"Oncogene"},{"issue":"2","key":"763_CR128","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/14712598.2012.646985","volume":"12","author":"S Almokadem","year":"2012","unstructured":"Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Th. 2012;12(2):251\u20137.","journal-title":"Expert Opin Biol Th"},{"issue":"23","key":"763_CR129","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","volume":"14","author":"AD Ricart","year":"2008","unstructured":"Ricart AD, Tolcher AW, Liu G, Holen K, Chwartz GS, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. Volociximab, a chimeric monoclonal antibody that specifically binds alpha(5)beta(1) integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008;14(23):7924\u20139.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"763_CR130","first-page":"455s","volume":"24","author":"LD Cranmer","year":"2006","unstructured":"Cranmer LD, Bedikian AY, Ribas A, O'Day S, Forero-Torres A, Yazji S, Kirkwood JM. Phase II study of volociximab (M200), an alpha 5 beta 1 anti-integrin antibody in metastatic melanoma. J Clin Oncol. 2006;24(18):455s.","journal-title":"J Clin Oncol"},{"issue":"1","key":"763_CR131","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"B Besse","year":"2013","unstructured":"Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha 5 beta 1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):90\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"763_CR132","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","volume":"121","author":"KM Bell-McGuinn","year":"2011","unstructured":"Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, et al. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011;121(2):273\u20139.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"763_CR133","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1167\/iovs.10-7097","volume":"52","author":"WQ Wang","year":"2011","unstructured":"Wang WQ, Wang FH, Lu FQ, Xu S, Hu WT, Huang JN, Gu Q, Sun XD. The antiangiogenic effects of integrin alpha 5 beta 1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophth Vis Sci. 2011;52(10):7213\u201320.","journal-title":"Invest Ophth Vis Sci"},{"issue":"11","key":"763_CR134","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/sj.bjc.6603171","volume":"94","author":"ME Cianfrocca","year":"2006","unstructured":"Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Brit J Cancer. 2006;94(11):1621\u20136.","journal-title":"Brit J Cancer"},{"issue":"8","key":"763_CR135","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1021\/acs.molpharmaceut.6b00800","volume":"14","author":"N Zhang","year":"2017","unstructured":"Zhang N, Xia YF, Zou Y, Yang WJ, Zhang J, Zhong ZY, Meng FH. ATN-161 peptide functionalized reversibly cross-linked Polymersomes mediate targeted doxorubicin delivery into melanoma-bearing C57BL\/6 mice. Mol Pharm. 2017;14(8):2538\u201347.","journal-title":"Mol Pharm"},{"issue":"11","key":"763_CR136","first-page":"3656s","volume":"7","author":"O Stoeltzing","year":"2001","unstructured":"Stoeltzing O, Liu W, Reinmuth N, Fan F, Livant DL, Mazar AP, Ellis LM. Reduction of colon cancer growth by a novel antiangiogenic agent that targets the integrin alpha 5 beta 1. Clin Cancer Res. 2001;7(11):3656s.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"763_CR137","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-014-2576-8","volume":"74","author":"J Mateo","year":"2014","unstructured":"Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang LL, Abbattista A, Davis C, Stampino CG, et al. A first-in-human study of the anti-alpha 5 beta 1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemoth Pharm. 2014;74(5):1039\u201346.","journal-title":"Cancer Chemoth Pharm"},{"issue":"2","key":"763_CR138","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/00008390-199404000-00006","volume":"4","author":"ED Berston","year":"1994","unstructured":"Berston ED, Ramos DM, Kramer RH. Metastatic melanoma-cells interact with the reticular fibers of the lymph-node. Melanoma Res. 1994;4(2):115\u201325.","journal-title":"Melanoma Res"},{"issue":"6","key":"763_CR139","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMc0706103","volume":"358","author":"JT Mullen","year":"2008","unstructured":"Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. New Engl J Med. 2008;358(6):647\u20138.","journal-title":"New Engl J Med"},{"issue":"7","key":"763_CR140","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/cam4.1098","volume":"6","author":"RA Sabol","year":"2017","unstructured":"Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, et al. Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the southern network on adverse reactions (SONAR). Cancer Med-Us. 2017;6(7):1541\u201351.","journal-title":"Cancer Med-Us"},{"issue":"10","key":"763_CR141","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/leu.2014.182","volume":"28","author":"YT Hsieh","year":"2014","unstructured":"Hsieh YT, Gang EJ, Shishido SN, Kim HN, Pham J, Khazal S, Osborne A, Esguerra ZA, Kwok E, Jang J, et al. OPEN effects of the small-molecule inhibitor of integrin alpha 4, TBC3486, on pre-B-ALL cells. Leukemia. 2014;28(10):2101\u20134.","journal-title":"Leukemia"},{"key":"763_CR142","doi-asserted-by":"crossref","unstructured":"Hsieh YT, Gang EJ, Bonig H, Biediger RJ, Vanderslice P, Kim YM. The small molecule inhibitor of VLA4 TBC3486 sensitizes resistant ALL to chemotherapy. Blood. 2012;120(21):1500.","DOI":"10.1182\/blood.V120.21.1500.1500"},{"issue":"3","key":"763_CR143","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.bmc.2008.02.067","volume":"17","author":"J Lee","year":"2009","unstructured":"Lee J, Hong JY, Nam TG, Peters EC, Orth AP, Geierstanger BH, Goldfinger LE, Ginsberg MH, Cho CY, Schultz PG. A small molecule inhibitor of alpha 4 integrin-dependent cell migration. Bioorgan Med Chem. 2009;17(3):977\u201380.","journal-title":"Bioorgan Med Chem"},{"issue":"2","key":"763_CR144","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bbrc.2017.07.096","volume":"491","author":"TN Lu","year":"2017","unstructured":"Lu TN, Ganganna B, Pham TT, Vo AV, Lu TP, Nguyen HGT, Nguyen MNT, Huynh PN, Truong NT, Lee J. Antitumor effect of the integrin alpha 4 signaling inhibitor JK273 in non-small cell lung cancer NCI-H460 cells. Biochem Bioph Res Co. 2017;491(2):355\u201360.","journal-title":"Biochem Bioph Res Co"},{"issue":"11","key":"763_CR145","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-07-6390","volume":"68","author":"CC Park","year":"2008","unstructured":"Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta(1) integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008;68(11):4398\u2013405.","journal-title":"Cancer Res"},{"issue":"53","key":"763_CR146","doi-asserted-by":"publisher","first-page":"44694","DOI":"10.1074\/jbc.M111.309450","volume":"287","author":"L Nissinen","year":"2012","unstructured":"Nissinen L, Koivunen J, Kapyla J, Salmela M, Nieminen J, Jokinen J, Sipila K, Pihlavisto M, Pentikainen OT, Marjamaki A, et al. Novel alpha 2 beta 1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor Preactivation. J Biol Chem. 2012;287(53):44694\u2013702.","journal-title":"J Biol Chem"},{"issue":"4","key":"763_CR147","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J. Opinion - angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273\u201386.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T09:52:13Z","timestamp":1604224333000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0763-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"23 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"92"}}